S., T., E., D., N., S., Y.-L., W., J.C.-H., Y., D.-T., C., . . . M., F. (2014). Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
Chicago Style CitationS., Thongprasert, et al. Health-related Quality-of-life in a Randomized Phase III First-line Study of Gefitinib Versus Carboplatin/paclitaxel in Clinically Selected Patients From Asia With Advanced NSCLC (IPASS). 2014.
MLA引文S., Thongprasert, et al. Health-related Quality-of-life in a Randomized Phase III First-line Study of Gefitinib Versus Carboplatin/paclitaxel in Clinically Selected Patients From Asia With Advanced NSCLC (IPASS). 2014.
警告：這些引文格式不一定是100％准確.